Short-Term Debt to Equity Ratio: Vigil Neuroscience, Inc. (VIGL)
The daily price chart for Vigil Neuroscience (VIGL) on the GURU.Markets platform reflects the dynamics of a company whose resilience relies on optimized biomaterial delivery, which minimizes disruptions and supports margins. This metric stands at 0.02, while the business is protected by exclusive patents and a high financial barrier to entry. A cohesive management team, which is developing strategic scientific partnerships with global behemoths, ensures price stability.
Analytical breakdowns for Vigil Neuro (VIGL)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Equity Ratio Vigil Neuroscience|VIGL - Long-Term Debt to Equity|Short-Term Debt to Capital Vigil Neuroscience|VIGL - Company Total Debt Obligations|Debts to Book Capitalization Vigil Neuroscience Inc.|VIGL - Long-Term Indebtedness|Company Short-Term Debts Vigil Neuroscience|Quick Liquidity vigilneuro.com
- company profitability and valuation multiples indicators:
Basic company analysis:Vigil Neuroscience, Inc.
As a biotechnology startup specializing in microglia therapy and TREM2 agonists, Vigil Neuroscience (VIGL) requires high liquidity, making the ratio of liabilities maturing within one year to equity critical for assessing financial stability. This metric measures the company's reliance on short-term borrowing relative to its net assets, allowing for the rapid diagnosis of default risks through the dynamics of short-term debt load to equity.
Competitor analysis
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|Short-Term Debt to Equity Ratio CPRX|Short-Term Debt to Equity DNLI|Short-Term Debt to Capital HRMY|Short-Term Debt to Capital Coefficient Biohaven Ltd|Short-Term Debt to Capital AMLX (Amylyx)|Short-Term Indebtedness to Equity Trevi Corp|Praxis Precision Medicines - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient anavex.com AVXL|CeriBell (CBLL) - Short-Term Debt to Equity|PRTA (Prothena Biosciences) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio ALEC|ANNX: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Omeros Corporation (OMER)|neurogene.com - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital ACIU (AC Immune SA)|Voyager Therapeutics Inc (VYGR) - Current Liabilities to Capital|NMRA: Short-Term Debt to Equity Ratio|SCLX - Short-Term Debt to Capital|Tevogen Bio Holdings (TVGN) - Short-Term Debt to Equity|Alpha Cognition Inc. - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Cognition Therapeutics, Inc.|Current Liabilities to Capital Inhibikase Therapeutics Inc IKT|Short-Term Debt to Equity Cassava (SAVA)|Short-Term Debt to Capital Coefficient assertiotx.com|Short-Term Debt to Capital COYA (Coya Therapeutics)|VTGN - Short-Term Debt to Equity Ratio|Ovid Rx - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient Acumen Pharmaceuticals Inc. ABOS|CRVO: Short-Term Debt to Capital|Current Liabilities to Capital Alterity Therapeutics Limited (ATHE)|Short-Term Debt to Equity Clene Inc|Short-Term Debt to Capital Ratio PEPG (PepGen Corp)|Short-Term Debt to Capital JUNS|Short-Term Debt to Equity Ratio Relmada Therapeutics Inc RLMD|Short-Term Debt to Capital ANVS (Annovis Bio Corp)|Grace Therapeutics Inc (GRCE) - Current Liabilities to Capital|AIFF: Short-Term Debt to Equity Ratio|KLTO: Short-Term Debt to Equity|NRSN: Short-Term Debt to Capital|RVPH - Short-Term Debt to Capital Coefficient|MTVA (MetaVia Inc.) - Short-Term Debt to Capital|NRXS - Short-Term Indebtedness to Equity|Short-Term Debt to Equity Helius Medical (HSDT)|Short-Term Debt to Equity PASG (passagebio.com)|Short-Term Debt to Equity Neuphoria Therapeutics NEUP|NERV: Short-Term Debt to Capital Ratio|Athira - Short-Term Debt to Capital|Current Liabilities to Capital Addex|ALZN (alzamend.com) - Short-Term Debt to Equity Ratio|Cyclerion Therapeutics, Inc. (CYCN) - Short-Term Debt to Capital|Short-Term Debt to Equity Protagenic Therapeutics Inc.|KTTA: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Cortigent, Inc. (CRGT)|ATXI - Current Liabilities to Capital|Brainstorm Cell - Short-Term Debt to Equity Ratio|caratherapeutics.com - Short-Term Debt to Equity|Chromocell Therapeutics Corp. - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient Eliem Therapeutics ELYM|ITCI: Short-Term Debt to Capital|Short-Term Indebtedness to Equity Longboard LBPH|MRNS (Marinus Pharmaceuticals) - Short-Term Debt to Capital|nkgenbiotech.com (NKGN) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity NeuroBo Pharmaceuticals, Inc. (NRBO)|Short-Term Debt to Equity SAGE (Sage Therapeutics Inc.)|Neurotrope - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital TRVN|WENA - Short-Term Debt to Equity|CERE (cerevel.com) - Short-Term Debt to Capital Ratio